0 317

Cited 0 times in

Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk

DC FieldValueLanguage
dc.contributor.author양영준-
dc.contributor.author이병권-
dc.contributor.author이상학-
dc.contributor.author장양수-
dc.date.accessioned2017-11-02T08:11:55Z-
dc.date.available2017-11-02T08:11:55Z-
dc.date.issued2017-
dc.identifier.issn0149-2918-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154188-
dc.description.abstractPURPOSE: The aim of this study was to evaluate the efficacy and tolerability of rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk. METHODS: This was a 12-week, randomized, double-blind, placebo-controlled, multicenter study. A total of 337 patients were screened. After a 4-week run-in period, 245 of these patients with high or moderately high risk as defined by the National Cholesterol Education Program Adult Treatment Panel III guidelines were randomly assigned. Patients received 1 of 6 regimens for 8 weeks as follows: (1) rosuvastatin 5 mg, (2) rosuvastatin 5 mg/ezetimibe 10 mg, (3) rosuvastatin 10 mg, (4) rosuvastatin 10 mg/ezetimibe 10 mg, (5) rosuvastatin 20 mg, or (6) rosuvastatin 20 mg/ezetimibe 10 mg. The primary outcome variable was percentage change in the level of LDL-C at week 8 of drug treatment. Secondary outcome variables included percentage changes of other lipid variables and achievement rates of LDL-C targets. Tolerability analyses were also performed. FINDINGS: The percentage change of LDL-C ranged from -45% to -56% (mean, -51%) in the monotherapy groups and from -58% to -63% (mean, -60%) in the combination therapy groups. The percentage change was greater in the pooled combination therapy group than in the counterpart (P < 0.001 for the pooled groups); this difference was more obvious for regimens with a lower statin dose. The percentage reductions of total cholesterol and triglycerides were greater in the combination groups than in the monotherapy groups. The LDL-C target achievement rates were 64% to 87% (mean, 73%) in the monotherapy groups and 87% to 95% (mean, 91%) in the combination groups (P = 0.01 for the pooled groups). The rates were significantly greater in patients receiving the combination therapy than in the monotherapy at lower doses of rosuvastatin. The proportions of patients with various adverse events were not significantly different between the groups. IMPLICATIONS: Rosuvastatin/ezetimibe combination therapy has better efficacy and target achievement rates than rosuvastatin monotherapy in patients with high cardiovascular risk.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherExcerpta Medica-
dc.relation.isPartOfCLINICAL THERAPEUTICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAnticholesteremic Agents/therapeutic use*-
dc.subject.MESHCardiovascular Diseases/etiology-
dc.subject.MESHCholesterol/blood-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHEzetimibe/administration & dosage*-
dc.subject.MESHFemale Humans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use-
dc.subject.MESHHypercholesterolemia/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRisk Factors-
dc.subject.MESHRosuvastatin Calcium/administration & dosage*-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTriglycerides/blood-
dc.titleCombination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYoung-June Yang-
dc.contributor.googleauthorSang-Hak Lee-
dc.contributor.googleauthorByung Soo Kim-
dc.contributor.googleauthorYun-Kyeong Cho-
dc.contributor.googleauthorHyun-Jai Cho-
dc.contributor.googleauthorKyoung Im Cho-
dc.contributor.googleauthorSeok-Yeon Kim-
dc.contributor.googleauthorJae Kean Ryu-
dc.contributor.googleauthorJin-Man Cho-
dc.contributor.googleauthorJoong-Il Park-
dc.contributor.googleauthorJong-Seon Park-
dc.contributor.googleauthorChang Gyu Park-
dc.contributor.googleauthorWoo Jung Chun-
dc.contributor.googleauthorMyung-A Kim-
dc.contributor.googleauthorDong-Kyu Jin-
dc.contributor.googleauthorNamho Lee-
dc.contributor.googleauthorByung Jin Kim-
dc.contributor.googleauthorKwang Kon Koh-
dc.contributor.googleauthorJon Suh-
dc.contributor.googleauthorSeung-Hwan Lee-
dc.contributor.googleauthorByoung-Kwon Lee-
dc.contributor.googleauthorSeung-Jin Oh-
dc.contributor.googleauthorHan-Young Jin-
dc.contributor.googleauthorYoungkeun Ahn-
dc.contributor.googleauthorSang-Gon Lee-
dc.contributor.googleauthorJang-Ho Bae-
dc.contributor.googleauthorWoo Jung Park-
dc.contributor.googleauthorSang-Chol Lee-
dc.contributor.googleauthorHan Cheol Lee-
dc.contributor.googleauthorJaewon Lee-
dc.contributor.googleauthorCheolwon Park-
dc.contributor.googleauthorBackhwan Lee-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1016/j.clinthera.2016.11.014-
dc.contributor.localIdA02793-
dc.contributor.localIdA02833-
dc.contributor.localIdA03448-
dc.contributor.localIdA02298-
dc.relation.journalcodeJ00614-
dc.identifier.eissn1879-114X-
dc.identifier.pmid28007331-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0149291816308529-
dc.subject.keywordLDL-
dc.subject.keywordcardiovascular diseases-
dc.subject.keywordcholesterol-
dc.subject.keyworddrug combinations-
dc.subject.keywordezetimibe-
dc.subject.keywordrosuvastatin calcium-
dc.contributor.alternativeNameYang, Young June-
dc.contributor.alternativeNameLee, Byoung Kwon-
dc.contributor.alternativeNameLee, Snag Hak-
dc.contributor.alternativeNameJang, Yang Soo-
dc.contributor.affiliatedAuthorLee, Byoung Kwon-
dc.contributor.affiliatedAuthorLee, Snag Hak-
dc.contributor.affiliatedAuthorJang, Yang Soo-
dc.contributor.affiliatedAuthorYang, Young June-
dc.citation.titleClinical Therapeutics-
dc.citation.volume39-
dc.citation.number1-
dc.citation.startPage107-
dc.citation.endPage117-
dc.identifier.bibliographicCitationCLINICAL THERAPEUTICS, Vol.39(1) : 107-117, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid42152-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.